OX40L blockade cellular nanovesicles for autoimmune diseases therapy

Area of Science:

• Immunology
• Nanotechnology
• Drug Delivery

Background:

• Current autoimmune disorder treatments lack specificity, causing adverse effects.
• Effector T cells and the OX40-OX40L pathway are key in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) pathogenesis.
• Targeting OX40-OX40L offers a potential strategy for selective immune modulation.

Purpose of the Study:

• To develop and evaluate cell membrane-derived nanovesicles (OX40 NVs) engineered to antagonize OX40-OX40L interactions for autoimmune disease therapy.
• To assess the targeting capabilities and therapeutic efficacy of OX40 NVs in preclinical models of RA and IBD.
• To investigate the combined therapeutic potential of OX40 NVs with dexamethasone (DEX) for RA treatment.

Main Methods:

• Engineering nanovesicles (NVs) from cell membranes to express OX40 receptors (OX40 NVs).
• In vitro assessment of OX40 NVs binding to inflamed endothelial cells (HUVECs).
• In vivo evaluation of OX40 NVs targeting in RA-inflamed joints and IBD-inflamed colons, and their therapeutic effects on disease progression, T cell populations, and cytokine levels.

Main Results:

• OX40 NVs demonstrated specific binding to inflamed HUVECs in vitro.
• OX40 NVs exhibited preferential accumulation in inflamed joints (RA) and colons (IBD) in vivo.
• Treatment with OX40 NVs significantly suppressed RA and IBD progression by reducing CD4+OX40+ T cells and pro-inflammatory cytokines, while enhancing regulatory T cells (Tregs), outperforming anti-OX40L therapy.
• Dexamethasone (DEX) loaded OX40 NVs further enhanced therapeutic potential for RA.

Conclusions:

• OX40 NVs represent a promising targeted therapy for autoimmune disorders by selectively blocking the OX40-OX40L pathway.
• The preferential localization and potent immune-suppressive ability of OX40 NVs offer a safer and more effective alternative to current non-specific immunomodulatory treatments.
• Further development of OX40 NVs holds significant potential for advancing autoimmune disease therapeutics.